Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) shares traded up 3% on Thursday . The company traded as high as C$2.74 and last traded at C$2.72. 11,567 shares were traded during mid-day trading, a decline of 88% from the average session volume of 93,972 shares. The stock had previously closed at C$2.64.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Stifel Nicolaus downgraded shares of Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and lowered their target price for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th. Ventum Financial increased their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a "buy" rating in a research note on Thursday, January 30th. Finally, Stifel Canada cut Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of C$5.49.
Check Out Our Latest Research Report on MDP
Medexus Pharmaceuticals Trading Down 1.4%
The firm has a market cap of C$64.48 million, a P/E ratio of 13.77 and a beta of 1.96. The business has a 50-day moving average price of C$2.55 and a 200-day moving average price of C$2.92.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
